Latest blog
CMC-001 has successfully passed two important milestones
At a recent Scientific Advice at EMA in London the agency has concluded that no further non-clinical studies are needed. This means that the non-clinical development program for CMC-001 has successfully been completed.
Another important milestone was reached with the recent finalization of the phase IIb clinical development. In this phase the dose-response relationship for CMC-001 has been established and the final dose for the phase III development program has been selected.
After these two important milestones have been passed the last o...
Read full length articleIntroduction
CMC Contrast AB
CMC Contrast AB was established in April 2000 with the purpose to develop targeted contrast media for MRI. Ideas and products have been patented, tested and developed in an extensive network of industrial partners, and academic partners and subcontractors. CMC Contrast AB is investor owned.
Read more about CMC Contrast
